Navigation Links
'Tumor Paint' Research Of Pediatric Oncologist Jim Olson Featured In Short Film -- A Sundance Festival Semifinalist
Date:11/27/2012

SEATTLE, Nov. 27, 2012 /PRNewswire/ -- A three-minute film about a tiny molecule that lights up brain tumors so neurosurgeons can better distinguish cancer from normal tissue has a chance to get its own moment in the spotlight as a semifinalist in the Sundance Film Festival in January.

"Bringing Light," (http://vimeo.com/51888804) which focuses on the "Tumor Paint" research led by James Olson, M.D., Ph.D., a clinical researcher at Fred Hutchinson Cancer Research Center and a pediatric oncologist at Seattle Children's Hospital, is available online for viewing and voting. Viewers have until Dec. 20 to cast their votes.

The film, directed by Bert Klasey, Chris Baron and James Allen Smith, also features neurosurgeon Richard Ellenbogen, M.D., chairman of the Department of Neurosurgery at the University of Washington School of Medicine, among others. It is part of a filmmaker competition called "Short Films, Big Ideas" sponsored by Focus Forward Films. Out of 30 total entries, five finalists will be screened at Sundance 2013 and the grand-prize winner will receive $100,000.

Olson's team developed Tumor Paint by re-engineering scorpion venom (chlorotoxin), which naturally targets brain cancer cells, by tagging it with a molecule that acts like a flashlight, causing brain tumors to "light up" during surgery so the margins can be seen more easily. The goal is to help surgeons remove as much cancer as possible while safely leaving normal brain tissue intact.

Tumor Paint is not yet in human use but is being developed by Blaze Bioscience, a Seattle biotech founded by Olson and Heather Franklin, president and CEO.

The potential of Tumor Paint is not limited to brain tumors; it has been found in preclinical studies to light up prostate, colon, breast and other cancers.  It is anticipated that human trials in cancer patients will begin next year.

If the human clinical trial results match the laboratory studies, Tumor Paint will enable surgeons to distinguish cancer tissue from non-cancerous tissue in real time as they operate. The ultimate goal is to save lives while also reducing problems caused by surgical removal of normal tissue in critical areas.

Another potential use for Tumor Paint is early detection of various forms of skin cancer. Olson and colleagues have demonstrated that it can light up non-pigmented skin cancers, which are sometimes difficult to detect and pose a greater threat to the patient if they are not detected early.

Olson gratefully points out that none of this research would have been possible without the support of private donors. "The work on Tumor Paint was funded primarily through financial gifts made to Fred Hutch and Seattle Children's Hospital by individuals, families and businesses that place their trust in our researchers to invent and develop new lifesaving therapies," he said.

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch's pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first and largest cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit www.fhcrc.org or follow Fred Hutch on Facebook, Twitter or YouTube.

This news release was issued on behalf of Newswise™. For more information, visit http://www.newswise.com.

Media Contacts:
Kristen Woodward
kwoodwar@fhcrc.org
206-667-5095


'/>"/>
SOURCE Fred Hutchinson Cancer Research Center
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market is Expected to Reach USD 7.9 billion by 2018: Transparency Market Research
2. Protein that helps tumor blood vessels mature could make cancer drugs more effective
3. CNIO researchers describe a new target for developing anti-angiogenic and anti-tumoral therapies
4. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
5. First targeted and programmable nanomedicine to show clinical antitumor effects published
6. Novel compound halts tumor spread, improves brain cancer treatment in animal studies
7. bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation
8. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
9. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
10. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
11. Nano-infused paint can detect strain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Cell therapies for a ... accelerated by research at Worcester Polytechnic Institute (WPI) that yielded a newly patented ... regeneration. , The novel method, developed by WPI faculty members Raymond Page, PhD, ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Last week, ... for corporate executives and entrepreneurs, held The Future of San Diego Life Science event ... San Diego life science community attended the event with speakers Dr. Rich Heyman, former ...
(Date:5/23/2016)... ... ... blood donations in South Texas and across the nation is growing. , But according to ... are on the decline. In fact, donations across the country are at their lowest point ... the last four years alone. , There is no substitute for blood. , “We want ...
(Date:5/23/2016)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... Board of Directors has approved the payment of a quarterly ... The cash dividend of $0.24 per share ... stockholders of record as of the close of business on ... approval of the Board of Directors and may be adjusted ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
Breaking Biology News(10 mins):